Kalaris Therapeutics, Inc. 8-K Filing

Ticker: KLRS · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1754068

Kalaris Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyKalaris Therapeutics, Inc. (KLRS)
Form Type8-K
Filed DateDec 17, 2025
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Kalaris Therapeutics, Inc. (ticker: KLRS) to the SEC on Dec 17, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share KLRS The Nasdaq).

How long is this filing?

Kalaris Therapeutics, Inc.'s 8-K filing is 6 pages with approximately 1,670 words. Estimated reading time is 7 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,670 words · 7 min read · ~6 pages · Grade level 14.4 · Accepted 2025-12-17 17:19:38

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share KLRS The Nasdaq

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risk and uncertainties. All statements, other than statements of historical fact, contained in this Current Report on Form 8-K, including statements regarding the strategy, future operations, prospects, plans and objectives of management of the Company, including the therapeutic potential of TH103 for nAMD and other exudative and neovascular retinal diseases, the anticipated timelines for reporting clinical data from the Phase 1a and Phase 1b/2 clinical trials of TH103, plans to advance TH103 into Phase 3 clinical trials and to develop TH103 for additional indications and the sufficiency of the Company's cash resources for the period anticipated, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on current expectations and beliefs of the management of the Company as well as assumptions made by, and information currently available to, the management of the Company and are subject to risks and uncertainties. There can be no assurance that future developments affecting the Company will be those that it has anticipated. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: risks associated with the clinical development and regulatory approval of TH103, including potential delays in the completion of clinical trials; expectations regardi

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release, dated December 17, 2025 99.2 Presentation, dated December 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALARIS THERAPEUTICS, INC. Date: December 17, 2025 By: /s/ Andrew Oxtoby Name: Andrew Oxtoby Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.